Neuralink and Synchron race to win FDA approval for brain implants
Elon Musk's brain implant company Neuralink and its rival Synchron are both moving through the US Food and Drug Administration (FDA) process, and either one could become the first company allowed to sell a brain-computer interface to the public. Fortune senior AI reporter Emily Forlini examined the competition in a report published November 21, 2026.
A brain-computer interface, or BCI, is a device placed in or near the brain that reads electrical signals from neurons and sends that data to a phone or computer. It lets a person control technology without moving.
The main numbers behind the race
- Neuralink's N1 implant is being used by about 26 people in its testing phase, up from seven patients a year earlier. All have severe disabilities.
- Synchron has implanted its Stentrode device in 15 people, five more than last year, according to founder and CEO Thomas Oxley.
- Neuralink has raised $1.3 billion, more than double the next-best-funded brain implant company. It was valued at roughly $9.7 billion by 2025.
- Synchron was valued at nearly $1 billion in its latest funding round.
- No brain implant is on the US market yet.
How the two devices differ
Neuralink's N1 requires a robotic arm to drill a circle into the patient's skull and place a quarter-size device on the brain tissue. The device carries 64 wires, each thinner than a human hair, with electrodes that pick up signals from neurons. Neuralink's first patient, Noland Arbaugh, who became paralyzed after a diving accident, received the implant in January 2024. He has used it to play video games such as Civilization, travel for speaking engagements, and work on a book with a writer.
Synchron's Stentrode is much less invasive. It takes about a two-hour surgery to insert through a blood vessel near the brain using a catheter, similar to a heart stent. A thin wire runs under the skin to a coin-size receiver in the chest near the collarbone. Patients activate it by thinking about a body part, such as "Move my foot," which an algorithm reads as a command like "Press select." Synchron was the first company to integrate with Apple's standardized, Bluetooth-powered BCI connection in 2025.
Oxley said Synchron is preparing a more powerful device that would reach more parts of the brain and still avoid skull surgery. He described the goal of whole-brain sensing as the field's "holy grail" and said such a device could act like a "cognitive copilot" for patients with aging-related cognitive decline or dementia. Neuralink, meanwhile, announced in June 2026 that it had performed its first procedure without breaking the dura, a protective layer around the brain.
What the FDA process looks like
Companies must pass through several stages before selling a device. The path starts with animal testing, then a first human implant and what are called early feasibility studies. After that comes the pivotal study, where companies expand to more patients and lock in their manufacturing line. Oxley called setting up the frozen manufacturing line "a huge investment." The pivotal study ends with FDA approval to sell the device to patients with clearly defined medical conditions, with insurance likely helping to cover costs.
Chad Bouton, CEO of BCI company Neuvotion, told Fortune: "I think in the next three or four years we might see an FDA clearance."
Privacy worries over brain data
The report raises the question of what people give up when companies gain access to brain data. Nita Farahany, a Duke University professor who wrote a book on protecting freedom of thought, told Fortune: "What you're thinking and feeling is your last space of true privacy. It's the most fundamental aspect of what it means to be human." She warned the world is heading toward "brain transparency," where companies could know what products people want before they do.
The report also suggests brain implants could bring a new wave of workplace monitoring, since the devices could record signals showing whether an employee is focused. Farahany wrote in her book that punitive brain surveillance is unlikely to be tolerated by the public, though people already accept other forms of workplace tracking.
AI's role and other players
The race began before AI became widely known with ChatGPT's debut in 2022, but the report says rapidly advancing AI could make implants far more powerful by helping them decipher thoughts and intentions. Matt Angle, CEO of Paradromics, said AI-enhanced BCIs might one day let people control humanoid robots or AI agents with their thoughts. He said implants could eventually understand a person's desires before they are aware of them, though "it won't be mainstream right away."
Other US companies in the field include Paradromics, which focuses on restoring speech, and Precision Neuroscience, which is building a brain interface for patients with paralysis. OpenAI CEO Sam Altman cofounded a BCI company called Merge Labs in 2025, and OpenAI invested in it in early 2026. A Merge Labs spokesperson said the company expects to share more about its product in "a couple months."
What is confirmed and what is not
Confirmed from the report: the patient counts, funding amounts, device details, FDA process stages, and statements from Oxley, Bouton, Angle, and Farahany. Predictions, such as how soon an FDA clearance might come or how implants could evolve with AI, are the views of the people quoted, not established facts. The report was cut off before completing its discussion of Neuralink's less invasive work with Convergent Research cofounder Adam Marblestone.
Why it matters
The first FDA-approved brain implant would mark the start of what industry figures expect to be a decades-long effort to connect human minds with machines. For the companies involved, the prize is a potentially large market for both the devices and the data they collect. For the public, the report argues the key question is what people gain, or lose, by giving companies access to their thoughts.